caa a22 4500 469026235 CHVBK 20180323132730.0 cr unu---uuuuu 170328e19920601xx s 000 0 eng 10.1007/BF01962704 doi (NATIONALLICENCE)springer-10.1007/BF01962704 Kupferberg Harvey Preclinical Pharmacology Section Epilepsy Branch, National Institute of Neurological Diseases and Stroke, National Institute of Health, Bethesda, Maryland, USA aut Strategies for identifying and developing new anticonvulsant drugs [Elektronische Daten] [Harvey Kupferberg] The identification of new anticonvulsant drugs depends on the use of different animal models of epilepsy. The models should be mechanism-independent, able to screen a large number of compounds, at limited cost and technical expertise. Primary screening models include genetic or reflex models of epilepsy and electrically and chemically induced seizures. Once active compounds have been identified, more advanced mechanistic and seizure-specific models are needed to refine the choice of a lead compound. These can be eitherin vivo orin vitro models. Models known to interact with specific receptors or the production of the putative neurotransmitters of neural excitability or inhibition are valuable in assessing possible mechanisms of action.In vitro models have evolved as important tools in correlating changes in electrical phenomena and therapeutic spectrum. The use of the hippocampal slice and the cultured neuron permits classification of anticonvulsant activity based on cellular actions of the drug. Interactions by the experimental drugs with specific subcellular fractions of the central nervous system augment information on possible mechanisms of action. The final choice of compounds for development requires synthesizing and comparing all of the pharmacodynamic information with the pharmacokinetic and toxicologic data. In the final analysis, no single animal model of epilepsy known today can assure the development of better drugs for all treatment of the epilepsies. Royal Dutch Association for Advancement of Pharmacy, 1992 Anticonvulsants nationallicence Disease models, animal nationallicence Drug screening nationallicence Epilepsy nationallicence Pharmaceutisch Weekblad Kluwer Academic Publishers 14/3(1992-06-01), 132-138 0031-6911 14:3<132 1992 14 11096 https://doi.org/10.1007/BF01962704 text/html Onlinezugriff via DOI 1 research-article jats NATIONALLICENCE 856 40 https://doi.org/10.1007/BF01962704 text/html Onlinezugriff via DOI NATIONALLICENCE 100 1- Kupferberg Harvey Preclinical Pharmacology Section Epilepsy Branch, National Institute of Neurological Diseases and Stroke, National Institute of Health, Bethesda, Maryland, USA aut NATIONALLICENCE 773 0- Pharmaceutisch Weekblad Kluwer Academic Publishers 14/3(1992-06-01), 132-138 0031-6911 14:3<132 1992 14 11096 Metadata rights reserved Springer special CC-BY-NC licence nationallicence BK010053 XK010053 XK010000 NATIONALLICENCE NATIONALLICENCE NL-springer